San Francisco – July 29, 2016 – Cooley advised the underwriters on Audentes Therapeutics' $85.1 million initial public offering. The company's common stock now trades on The NASDAQ Global Market under the symbol "BOLD."

BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as joint book-running managers for the offering. Wedbush PacGrow acted as co-manager.

Audentes Therapeutics is a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects.

The Cooley corporate and securities team advising the underwriters included Drew Williamson, Charlie Kim, David Peinsipp, Jonie Kondracki, Denny Won and Caleb Greig.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.